---
document_datetime: 2025-11-23 08:01:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/viracept.html
document_name: viracept.html
version: success
processing_time: 0.1103356
conversion_datetime: 2025-12-28 11:49:00.054641
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Viracept

[RSS](/en/individual-human-medicine.xml/66218)

##### Withdrawn

This medicine's authorisation has been withdrawn

nelfinavir

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Viracept](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 January 1998 the European Commission granted a marketing authorisation for the whole European Union to Roche Registration Limited for Viracept (nelfinavir), an antiretroviral agent of the protease inhibitor class. Viracept was indicated for use in antiretroviral combination treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children of 3 years of age and older. The marketing authorisation was valid for a 5-year period. It subsequently was renewed for additional 5-year periods in 2003 and 2008. Before the expiry of the last 5-year period of validity the Marketing Authorisation Holder did not apply to renew the marketing authorisation.

Consequently, the marketing authorisation for Viracept expired on 23 January 2013. The European Public Assessment Report for Viracept is updated accordingly to reflect that the marketing authorisation is no longer valid.

Viracept : EPAR - Summary for the public

English (EN) (527.82 KB - PDF)

**First published:** 27/08/2008

**Last updated:** 10/06/2014

[View](/en/documents/overview/viracept-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-392)

български (BG) (693.61 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/bg/documents/overview/viracept-epar-summary-public_bg.pdf)

español (ES) (590.94 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/es/documents/overview/viracept-epar-summary-public_es.pdf)

čeština (CS) (658.57 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/cs/documents/overview/viracept-epar-summary-public_cs.pdf)

dansk (DA) (607.29 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/da/documents/overview/viracept-epar-summary-public_da.pdf)

Deutsch (DE) (533.56 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/de/documents/overview/viracept-epar-summary-public_de.pdf)

eesti keel (ET) (528.98 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/et/documents/overview/viracept-epar-summary-public_et.pdf)

ελληνικά (EL) (701.81 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/el/documents/overview/viracept-epar-summary-public_el.pdf)

français (FR) (592.4 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/fr/documents/overview/viracept-epar-summary-public_fr.pdf)

italiano (IT) (593.21 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/it/documents/overview/viracept-epar-summary-public_it.pdf)

latviešu valoda (LV) (665.41 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/lv/documents/overview/viracept-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (610.99 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/lt/documents/overview/viracept-epar-summary-public_lt.pdf)

magyar (HU) (650.57 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/hu/documents/overview/viracept-epar-summary-public_hu.pdf)

Malti (MT) (678.18 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/mt/documents/overview/viracept-epar-summary-public_mt.pdf)

Nederlands (NL) (591.12 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/nl/documents/overview/viracept-epar-summary-public_nl.pdf)

polski (PL) (657.47 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/pl/documents/overview/viracept-epar-summary-public_pl.pdf)

português (PT) (590.72 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/pt/documents/overview/viracept-epar-summary-public_pt.pdf)

română (RO) (619.86 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/ro/documents/overview/viracept-epar-summary-public_ro.pdf)

slovenčina (SK) (656.11 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/sk/documents/overview/viracept-epar-summary-public_sk.pdf)

slovenščina (SL) (591.18 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/sl/documents/overview/viracept-epar-summary-public_sl.pdf)

Suomi (FI) (528.83 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/fi/documents/overview/viracept-epar-summary-public_fi.pdf)

svenska (SV) (590.6 KB - PDF)

**First published:**

27/08/2008

**Last updated:**

10/06/2014

[View](/sv/documents/overview/viracept-epar-summary-public_sv.pdf)

## Product information

Viracept : EPAR - Product Information

English (EN) (1.87 MB - PDF)

**First published:** 08/08/2008

**Last updated:** 10/06/2014

[View](/en/documents/product-information/viracept-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-129)

български (BG) (5.46 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/bg/documents/product-information/viracept-epar-product-information_bg.pdf)

español (ES) (1.56 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/es/documents/product-information/viracept-epar-product-information_es.pdf)

čeština (CS) (2.65 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/cs/documents/product-information/viracept-epar-product-information_cs.pdf)

dansk (DA) (1.54 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/da/documents/product-information/viracept-epar-product-information_da.pdf)

Deutsch (DE) (1.59 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/de/documents/product-information/viracept-epar-product-information_de.pdf)

eesti keel (ET) (1.88 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/et/documents/product-information/viracept-epar-product-information_et.pdf)

ελληνικά (EL) (3.7 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/el/documents/product-information/viracept-epar-product-information_el.pdf)

français (FR) (1.61 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/fr/documents/product-information/viracept-epar-product-information_fr.pdf)

íslenska (IS) (1.46 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/is/documents/product-information/viracept-epar-product-information_is.pdf)

italiano (IT) (1.49 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/it/documents/product-information/viracept-epar-product-information_it.pdf)

latviešu valoda (LV) (2.81 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/lv/documents/product-information/viracept-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.3 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/lt/documents/product-information/viracept-epar-product-information_lt.pdf)

magyar (HU) (2.53 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/hu/documents/product-information/viracept-epar-product-information_hu.pdf)

Malti (MT) (3.27 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/mt/documents/product-information/viracept-epar-product-information_mt.pdf)

Nederlands (NL) (1.58 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/nl/documents/product-information/viracept-epar-product-information_nl.pdf)

norsk (NO) (1.53 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/no/documents/product-information/viracept-epar-product-information_no.pdf)

polski (PL) (3.52 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/pl/documents/product-information/viracept-epar-product-information_pl.pdf)

português (PT) (1.56 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/pt/documents/product-information/viracept-epar-product-information_pt.pdf)

română (RO) (2.48 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/ro/documents/product-information/viracept-epar-product-information_ro.pdf)

slovenčina (SK) (2.56 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/sk/documents/product-information/viracept-epar-product-information_sk.pdf)

slovenščina (SL) (2.61 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/sl/documents/product-information/viracept-epar-product-information_sl.pdf)

Suomi (FI) (1.54 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/fi/documents/product-information/viracept-epar-product-information_fi.pdf)

svenska (SV) (1.46 MB - PDF)

**First published:**

08/08/2008

**Last updated:**

10/06/2014

[View](/sv/documents/product-information/viracept-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0121 23/01/2013

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Viracept : EPAR - All Authorised presentations

English (EN) (1.87 MB - PDF)

**First published:** 04/07/2008

**Last updated:** 10/06/2014

[View](/en/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_en.pdf)

[Other languages (20)](#file-language-dropdown-687)

български (BG) (660.04 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/bg/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_bg.pdf)

español (ES) (133.37 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/es/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_es.pdf)

čeština (CS) (205.14 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/cs/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (133.47 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/da/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (133.22 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/de/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (134 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/et/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (207.66 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/el/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_el.pdf)

français (FR) (133.13 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/fr/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (460.36 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/it/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (207.47 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/lv/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (162.77 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/lt/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (205.31 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/hu/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (132.25 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/nl/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_nl.pdf)

polski (PL) (170.2 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/pl/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_pl.pdf)

português (PT) (133.62 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/pt/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_pt.pdf)

română (RO) (197.22 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/ro/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (205.13 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/sk/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (132.93 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/sl/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (133.36 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/fi/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (133.13 KB - PDF)

**First published:**

04/07/2008

**Last updated:**

10/06/2014

[View](/sv/documents/all-authorised-presentations/viracept-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Viracept Active substance nelfinavir International non-proprietary name (INN) or common name nelfinavir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AE04

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older.

In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.

## Authorisation details

EMA product number EMEA/H/C/000164 Marketing authorisation holder

Roche Registration Ltd.

6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom

Marketing authorisation issued 22/01/1998 Withdrawal of marketing authorisation 23/01/2013 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Viracept : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.12 MB - PDF)

**First published:** 06/10/2008

**Last updated:** 10/06/2014

[View](/en/documents/procedural-steps-after/viracept-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Viracept-H-C-164-II-119 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/764761/2011

English (EN) (741.61 KB - PDF)

**First published:** 02/12/2011

**Last updated:** 10/06/2014

[View](/en/documents/variation-report/viracept-h-c-164-ii-119-epar-assessment-report-variation_en.pdf)

Viracept-H-C-164-II-120: EPAR - Assessment Report - Variation

Adopted

English (EN) (389.58 KB - PDF)

**First published:** 29/06/2011

**Last updated:** 10/06/2014

[View](/en/documents/variation-report/viracept-h-c-164-ii-120-epar-assessment-report-variation_en.pdf)

Viracept-H-C-164-Z-109 : EPAR - Assessment Report - Lifting of suspension

Reference Number: EMEA/CHMP/492059/2007

English (EN) (465.68 KB - PDF)

**First published:** 22/11/2007

**Last updated:** 10/06/2014

[View](/en/documents/variation-report/viracept-h-c-164-z-109-epar-assessment-report-lifting-suspension_en.pdf)

Viracept-H-C-164-A20-107 : EPAR - Scientific Conclusion - Article 20

English (EN) (147.7 KB - PDF)

**First published:** 15/08/2007

**Last updated:** 10/06/2014

[View](/en/documents/scientific-conclusion/viracept-h-c-164-a20-107-epar-scientific-conclusion-article-20_en.pdf)

Viracept : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (297.47 KB - PDF)

**First published:** 20/11/2006

**Last updated:** 10/06/2014

[View](/en/documents/steps-after-cutoff/viracept-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Viracept : EPAR - Scientific Discussion

English (EN) (455.81 KB - PDF)

**First published:** 20/11/2006

**Last updated:** 10/06/2014

[View](/en/documents/scientific-discussion/viracept-epar-scientific-discussion_en.pdf)

Viracept : EPAR - Procedural steps taken before authorisation

English (EN) (219.59 KB - PDF)

**First published:** 20/11/2006

**Last updated:** 10/06/2014

[View](/en/documents/procedural-steps/viracept-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Viracept

[European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection](/en/news/european-medicines-agency-finalises-review-medicines-concerned-roche-pharmacovigilance-inspection) 19/11/2013

[European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations](/en/news/european-medicines-agency-starts-infringement-procedure-investigate-roches-alleged-non-compliance-pharmacovigilance-obligations) 23/10/2012

[Studies assessed by the European Medicines Agency indicate no increased risk of developing cancer for patients who have taken Viracept contaminated with ethyl mesilate](/en/news/studies-assessed-european-medicines-agency-indicate-no-increased-risk-developing-cancer-patients-who-have-taken-viracept-contaminated-ethyl-mesilate) 24/07/2008

[European Medicines Agency agrees on action plan following the recall of Viracept and recommends suspension of the marketing authorisation](/en/news/european-medicines-agency-agrees-action-plan-following-recall-viracept-recommends-suspension-marketing-authorisation) 21/09/2007

[European Medicines Agency recommends lifting of suspension for Viracept](/en/news/european-medicines-agency-recommends-lifting-suspension-viracept) 20/09/2007

[European Medicines Agency announces recall of Viracept](/en/news/european-medicines-agency-announces-recall-viracept) 06/06/2007

**This page was last updated on** 10/06/2014

## Share this page

[Back to top](#main-content)